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.2012.05.0Abstract This paper describes sensitive, accurate and precise spectrophotometric, TLC-spectro-
densitometric and high performance liquid chromatographic (HPLC) methods for simultaneous
determination of olanzapine and ﬂuoxetine HCl. Two spectrophotometric methods were developed,
namely; ﬁrst derivative (D1) and derivative ratio (DD1) methods. The TLC method employed
aluminum TLC plates precoated with silica gel GF254 as the stationary phase and methanol:
toluene:ammonia (7:3:0.1, by volume) as the mobile phase, where the chromatogram was scanned
at 235 nm. The developed HPLC method used a reversed phase C18 column with isocratic elution.
The mobile phase composed of phosphate buffer pH 4.0:acetonitrile:triethylamine (53:47:0.03, by
volume) at ﬂow rate of 1.0 mL min1. Quantitation was achieved with UV detection at 235 nm.
The methods were validated according to the International Conference on Harmonization (ICH)
guidelines. The selectivity of the proposed methods was tested using laboratory-prepared mixtures.
The developed methods were successfully applied for the determination of olanzapine and ﬂuoxe-
tine HCl in bulk powder and combined capsule dosage form.
ª 2012 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Olanzapine (OLZ) is an atypical antipsychotic drug, approved
by the FDA for the treatment of schizophrenia and bipolar639307; fax: +20 223628426.
m (M.A. Tantawy).
o University.
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04disorder. It is chemically designated as 2-methyl-4-(4-methyl-
1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine, Fig. 1A.
It has a higher afﬁnity for 5-HT2 serotonin receptors than
D2 dopamine receptors. The mode of action of Olanza-
pine’s antipsychotic activity is unknown [1]. Fluoxetine HCl
(FLX) is an antidepressant of the selective serotonin reuptake
inhibitor (SSRI) class. It is chemically designated as N-methyl-
3-phenyl-3-[4-(triﬂuoromethyl)phenoxy]propan-1-amine, Fig.
1B. It is used for the treatment of depression. Being one of
SSRI drugs, it acts by increasing the extracellular level of the
neurotransmitter serotonin by inhibiting its reuptake into the
cell [1]..V. All rights reserved.
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(b) The structure of fluoxetine HCl. 
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Fig. 1 The structures of olanzapine and ﬂuoxetine HCl.
174 M.A. Tantawy et al.Determination of OLZ was carried out by HPLC [2–6], UV
spectrophotometry [2,7], CZE [2] and linear voltammetry [2].
For FLX, it was determined by UV spectrophotometry [8–
10] and HPLC [11,12].
There is no ofﬁcial method for the determination of OLZ
and FLX in dosage form. There are few reported methods
for their simultaneous analysis including three HPLC methods
[13–15] and two HPTLC methods [14,15].
So, the aim of this work was to develop recent, simple, sen-
sitive and validated spectrophotometric methods, TLC-spec-
trodensitometric method and HPLC chromatographic
method for the simultaneous determination of OLZ and
FLX in their pure powdered form, laboratory prepared mix-
tures and in their pharmaceutical capsule dosage form. The
spectrophotometric methods applied are ﬁrst derivative (D1)
and derivative ratio (DD1) method. The developed methods
can be successfully applied in routine analysis and quality con-
trol laboratories.
Experimental
Apparatus
Spectrophotometric measurements were carried out on a dual
beam Shimadzu (Kyoto, Japan) UV–Vis. spectrophotometer,
model UV-1601 PC connected to IBM compatible with an
Hp 600inkjet printer. The bundle software, UV PC personal
spectroscopy software version 3.7 (Shimadzu, Kyoto, Japan)was used to process absorption and derivative spectra, the
spectral band width was 2 nm and scanning speed was
2800 nm min1.
The TLC system comprised a Camag Linomat autosampler
(Switzerland), Camag microsyringe (100-lL), and Camag TLC
scanner 35/N/30319 with winCATS software, a short wave-
length UV lamp emitting at 254 nm (Desaga,Germany) and
TLC plates precoated with silica gel GF254 20 · 20 cm,
0.25 mm thickness (E. Merck, Darmstadt, Germany).
The HPLC system comprised an Agilent pump with differ-
ent ﬂow rates (model 1100 series, Agilent, USA), equipped
with a variable wavelength detector and a 20-lL volume injec-
tion loop. A Zorbax ODS (5 lm, 25 · 4.6 mm i.d.) column was
used as stationary the phase. The samples were injected with a
50-lL Hamilton analytical syringe.
Materials
Pure samples
Olanzapine and ﬂuoxetine HCl were kindly supplied by Eli
Lilly Company – Egypt. Their purity was found to be
100.00% and 99.92% for OLZ and FLX, respectively accord-
ing to a reported HPLC method [14].
Pharmaceutical dosage form
Symbyax (3 mg/25 mg) (Eli Lilly and Company – USA)
Batch No. A588272A, labeled to contain 3 mg olanzapine
and 25 mg ﬂuoxetine HCl per capsule.
 (a) Zero order absorption spectra of 7.5 µg mL-1
 olanzapine (- - -) and                     200 µg mL-1
 fluoxetine HCl (        ) using methanol as a blank. 
(b) First derivative absorption spectra of 7.5 µg mL-1
 olanzapine (- - -) and              200 µg mL-1
 fluoxetine HCl   (       ) using methanol as a blank. 
Fig. 2 D0 and D1 Spectra of olanzapine and ﬂuoxetine HCl.
Fig. 4 TLC chromatogram of a resolved mixture of olanzapine
(6 lg band1) and ﬂuoxetine HCl (25 lg band1).
Simultaneous determination of olanzapine and ﬂuoxetine hydrochloride in capsules 175Chemicals and reagents
All chemicals used throughout the work were of analytical
grade and solvents were of spectroscopic and HPLC grade:
Methanol (Merck, Germany), acetonitrile (Merck, Ger-
many), triethylamine (Sigma–Aldrich, Belgium), phosphate
buffer solution pH 4.0 [16], toluene (Adwic, Egypt), ammonia
solution 33% (Adwic, Egypt) and double distilled deionized
water (Otsuka, Cairo, Egypt).
Solutions
Stock standard solutions
Stock standard solutions of OLZ (4 mg mL1) and FLX
(20 mg mL1) were prepared in methanol.-1 5 – 17.5 µg mL   using the        spectrum of 200 µg mL-1
 of fluoxetine HCl as a divisor, methanol was used as a blank.        
(a) First derivative of ratio spectra of olanzapine  
Fig. 3 DD1 spectra of olanzWorking standard solutions
For spectrophotometric methods. Working solutions of OLZ
(50 lg mL1) and FLX (1 mg mL1) were prepared from their
respective stock solutions using methanol as a solvent.
For TLC-spectrodensitometric method. Working solutions of
OLZ (1 mg mL1) and FLX (10 mg mL1) were prepared
from their respective stock solutions using methanol as a
solvent.
For HPLC method. Working solutions of OLZ (100 lg mL1)
and FLX (1 mg mL1) were prepared from their respective
stock solutions using methanol as a solvent.
Laboratory-prepared mixtures
Solutions containing different ratios of OLZ and FLX were
prepared by transferring aliquots from their working solutions
into a series of 10-ml volumetric ﬂasks and the volume of each
was completed to the mark with methanol in case of spectro-
photometry and TLC spectro-densitometry. For HPLC, the
volume was completed to the mark with the mobile phase.       
(b) First derivative of ratio spectra of fluoxetine 
HCl 100 – 600 µg mL-1 using the spectrum of 12.5 µg mL-1 
 of olanzapine as a divisor, methanol was used as a blank.    
apine and ﬂuoxetine HCl.
Fig. 5 HPLC chromatogram of 30 lg mL1 olanzapine and
500 lg mL1 ﬂuoxetine HCl.
176 M.A. Tantawy et al.Procedures
Construction of the calibration curves
For spectrophotometric method. For D1 spectrophotometric
method. Aliquots equivalent to 50–175 lg of OLZ and 1000–
6000 lg of FLX were accurately measured and transferred
from their working solutions into a set of 10-ml volumetric
ﬂasks and the volumes were completed to the mark with meth-
anol. The zero order and the ﬁrst derivative spectra were re-
corded. The peak amplitudes of the obtained ﬁrst derivative
spectra were measured at 292 nm for OLZ and at 270 nm for
FLX.
For DD1 spectrophotometric method. The zero order
absorption spectra of OLZ (5–17.5 lg mL1) and FLX (100–
600 lg mL1) were measured and divided by the absorptionTable 1 Assay parameters and validation sheet for determination o
Parameter OLZ
D1 DD1 TLC HP
Range 5–17.5 lg mL1 1–8 lg band1 20–
Slope 0.0261 0.1819 Slope 1a = 307.257 0.01
Slope 2a = 7226.1
Intercept 0.0006 0.0096 1319.8 0
Mean of R (%) 99.98 100.04 99.93 100
SD of R (%) 0.828 0.608 0.725 0
Variance 0.686 0.370 0.525 0
Correlation coeﬃcient (r) 0.9998 0.9999 0.9999 0
Repeatabilityb (%) 0.500 0.721 0.789 0
Intermediate precisionb (%) 0.729 0.743 0.812 0
a Slope 1 and 2 are the coefﬁcients of X2 and X, respectively. Following
peak area, x is the concentration of Olanzapine or Fluoxetine (lg band
b Average of three determinations.spectra of 200 lg mL1 FLX and 12.5 lg mL1 OLZ, respec-
tively. The ﬁrst derivative of the obtained spectra was re-
corded. The peak amplitudes of the obtained DD1 spectra
were measured at 270 nm for OLZ and at 278 nm for FLX.
For TLC-spectrodensitometric method. Aliquots equivalent to
1–8 mg of OLZ and 10–60 mg of FLX were accurately mea-
sured and transferred from their working standard solutions
into a set of 10-ml volumetric ﬂasks and the volumes were
completed to the mark with methanol. A 10-lL aliquot of each
solution was applied to the TLC plates, and the plates were
developed to a distance of about 9.5 cm by the ascending tech-
nique using methanol: toluene: ammonia (7: 3: 0.1, by volume)
as the mobile phase. The plates were then removed, air-dried,
and the spots were visualized under a UV lamp at 254 nm. The
chromatogram was scanned at 235 nm. Two calibration curves
representing the relationship between the recorded area under
the peak and the corresponding concentrations of the drugs in
micrograms per band were plotted.
For HPLC method. Aliquots equivalent to 200–1000 lg of
OLZ and 1000–6000 lg of FLX were accurately measured
and transferred from their working solutions into a set of
10-ml volumetric ﬂasks and the volumes were completed to
the mark with the mobile phase [Phosphate buffer pH 4.0:
acetonitrile: triethylamine (53:47:0.03, by volume)]. A 20-lL
aliquot of each solution was injected onto a Zorbax ODS col-
umn (5 lm, 250 · 4.6 mm i.d.), using the mobile phase, at ﬂow
rate 1.0 mL min1 and detection at 235 nm. Two calibration
curves were constructed by plotting the peak area ratios, using
50 lg mL1 of OLZ and 200 lg mL1 of FLX as the external
standards (the divisors), against the corresponding concentra-
tion of each drug in micrograms per milliliter.
Assay of laboratory-prepared mixtures
For spectrophotometric methods. The absorption spectra of the
laboratory-prepared mixtures were scanned, processed as un-
der calibration for each of the proposed methods and the con-
centration of OLZ and FLX in each mixture was calculated
using the speciﬁed regression equation.
For TLC-spectrodensitometric and HPLC methods. The peak
areas or peak area ratios of the laboratory-prepared mixturesf olanzapine and ﬂuoxetine HCl by the proposed methods.
FLX
LC D1 DD1 TLC HPLC
100 lg mL1 100–600 lg mL1 10–60 lg band1 100–600 lg mL1
8 0.0021 0.0041 Slope 1a = 3.369 0.005
Slope 2a = 511.8
.086 0.0066 0.0593 7362.3 0.004
.00 100.33 100.26 99.99 99.83
.890 0.521 0.421 0.297 0.729
.792 0.271 0.177 0.088 0.531
.9998 1.0000 0.9999 1.0000 0.9999
.982 0.252 0.431 0.151 0.511
.959 0.270 0.404 0.162 0.533
a polynomial regression A= ax2 + bx+ cWhere, A is the integrated
1), a and b are coefﬁcients 1 and 2, respectively and c is the intercept.
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Simultaneous determination of olanzapine and ﬂuoxetine hydrochloride in capsules 177were scanned and processed as described for the calibration for
each of the proposed TLC and HPLC methods, respectively.
The concentrations of OLZ and FLX in each mixture were cal-
culated using the speciﬁed regression equations.
Application to pharmaceutical preparations
For spectrophotometric methods. Twenty capsules of Sym-
byax (3 mg/25 mg) were evacuated, accurately weighed and
ﬁnely powdered. Accurately weighed portions equivalent to
12 mg OLZ and 100 mg FLX, respectively were transferred
into 100-mL beakers, sonicated in 30 mL methanol for
10 min and ﬁltered into 100-mL volumetric ﬂasks. The residues
were washed three times each using 10 mL methanol and the
solution was completed to the mark with the same solvent.
Aliquots of 1.0 mL were transferred from the prepared solu-
tions to 10-mL volumetric ﬂasks and diluted with methanol
for spectrophotometric determination of both drugs. The gen-
eral procedure previously described under each method was
followed to determine the concentration of each drug in the
prepared dosage form solutions.
For TLC-spectrodensitometric and HPLC methods. Forty cap-
sules of Symbyax (3 mg/25 mg) were evacuated, accurately
weighed and ﬁnely powdered. Accurately weighed portions
equivalent to 60 mg OLZ and 500 mg FLX respectively, were
transferred into 100-mL beakers, sonicated in 30 mL methanol
for 10 min, and ﬁltered into 100-mL volumetric ﬂasks. The res-
idues were washed three times each using 10 mL methanol and
the solution was completed to the mark with the same solvent.
Aliquots of 5.0 mL were transferred from the prepared solu-
tions to 10-mL volumetric ﬂasks and diluted with methanol
for TLC-spectrodensitometric determination of both drugs,Table 2 Determination of olanzapine and ﬂuoxetine HCl in
laboratory prepared mixtures by spectrophotometric methods.
Concentration (lg mL1) OLZ FLX
OLZ FLX D1 DD1 D1 DD1
17.5 100 99.95 100.00 101.05 99.20
12.0 100 100.60 100.45 100.88 99.99
05.0 100 99.96 100.60 100.60 100.42
17.5 200 100.67 100.30 100.70 99.70
10.0 100 100.20 100.00 100.65 99.65
Mean 100.28 100.27 100.78 99.79
RSD 0.344 0.268 0.186 0.451
Table 3 Determination of olanzapine and ﬂuoxetine HCl in
laboratory prepared mixtures by TLC spectro-densitometric
and HPLC methods.
OLZ: FLX OLZ FLX
TLC HPLC TLC HPLC
3:25 98.83 100.63 99.76 99.76
1:2 99.00 100.78 99.90 98.65
1:3 99.00 100.66 100.23 99.43
1:4 99.20 100.64 100.05 100.36
Mean 99.01 100.68 99.99 99.55
RSD 0.153 0.069 0.202 0.716
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178 M.A. Tantawy et al.where 10 lL was applied onto TLC plates. For HPLC analy-
sis, the last solution was further diluted by transferring
1.0 mL aliquots of it to 10-mL volumetric ﬂasks and the vol-
umes were completed with the HPLC mobile phase. The gen-
eral procedures described above for each method were
followed to determine the concentration of OLZ and FLX in
the prepared dosage form solutions.
Results and discussion
Spectrophotometric methods
First derivative method (D1)
The zero order absorption spectra of OLZ and FLX show se-
vere overlapping that prevents the use of direct spectropho-
tometry for their analysis without preliminary separation,
Fig. 2A. In the ﬁrst derivative spectrophotometry, the zero or-
der absorption spectra of OLZ and FLX are obtained and then
the ﬁrst derivative of the obtained spectra was recorded using
Dk= 4 nm and a scaling factor of 10, Fig. 2B. The peak
amplitudes of the obtained ﬁrst derivative spectra were mea-
sured at 292 nm for OLZ and 270 for FLX. The ﬁrst derivative
spectroscopy was applied to solve the problem of the over-
lapped absorption spectra of the cited drugs.
The regression equations were computed for OLZ and FLX
and found to be:
D1 ¼ 0:0261C 0:0006 ðfor OLZÞ
D1 ¼ 0:0021Cþ 0:0066 ðfor FLXÞ
where D1 is the peak amplitude and C is the corresponding
concentration in lg mL1.
Derivative ratio method (DD1)
In the derivative ratio spectrophotometry, the absorption spec-
trum of the mixture is obtained and divided by the absorption
spectrum of the standard solution of one of the components,
and the ﬁrst derivative of the ratio spectrum is obtained. First
derivative ratio spectrophotometric method DD1 was applied
to solve the problem of the overlapped absorption spectra of
the cited drugs.
Different concentrations of OLZ and FLXwere investigated
as divisors. The divisor concentrations 12.5 lg mL1 and
200 lg mL1 of OLZ and FLX, respectively, were found the
best regarding average recovery percent when they were used
for the prediction of OLZ and FLX concentrations in bulk pow-
der as well as in laboratory-preparedmixtures. The obtained ra-
tio spectra were differentiated with respect to wavelength usingTable 5 Parametrs required for system suitability test of TLC-spec
Parameters TLC
OLZ FLX
Retention time (tR) [min.]
Retardation factor (Rf) 0.30 0.70
Resolution (Rs) 3.56
Tailing factor (T) 0.833 0.714
Capacity factor (K0)
Selectivity factor (a) 2.333
Column eﬃciency (N)
Height equivalent to theoretical plate (HETP) (mm)scaling factor 10 and Dk= 4, Fig. 3A and B. The peak ampli-
tudes showed good linearity and accuracy at 270 nm and
278 nm for OLZ and FLX, respectively. The regression equa-
tions were computed for OLZ and FLX and found to be:
DD1 ¼ 0:1819C 0:0096 ðfor OLZÞ
DD1 ¼ 0:0041C 0:0593 ðfor FLXÞ
where DD1 is the peak amplitude and C is the corresponding
concentration in lg mL1.
TLC-spectrodensitometric method
Several trials were done to choose a developing system which
can separate OLZ from FLX. Satisfactory separation was ob-
tained using the system methanol: Toluene: ammonia (7:3:0.1,
by volume) as the mobile phase. Rf values were 0.3 ± 0.02 and
0.7 ± 0.02 for OLZ and FLX, respectively as shown in Fig. 4.
This separation allows the determination of OLZ and FLX at
235 nm without any interference from each other. A polyno-
mial relationship was found to exist between the integrated
area under the peak of the separated spots at the selected
wavelength (235 nm) and the corresponding concentration of
OLZ in the range of 1–8 lg band1 and in the range of 10–
60 lg band1 in case of FLX. The regression equations were
computed for OLZ and FLX and found to be:
A ¼ 307:257C2 þ 7226:1Cþ 1319:8 ðfor OLZÞ
A ¼ 3:369C2 þ 511:8Cþ 7362:3 ðfor FLXÞ
where A is the integrated peak area under the peak and C is the
corresponding concentration in lg band1.
HPLC method
Good chromatographic separation of the two drugs in their
binary mixtures could be achieved by using a Zorbax ODS col-
umn (5 lm, 250 · 4.6 mm i.d.) with a mobile phase consisting
of Phosphate buffer pH 4: acetonitrile: triethylamine
(53:47:0.03, by volume) followed by UV detection at 235 nm,
Fig. 5. Several trials have been undertaken to reach the opti-
mum stationary/mobile phases matching. The suggested chro-
matographic system allows complete base line separation at
reasonable time. The linearity of the detector’s response of
the studied drugs was determined by plotting peak area ratios
(calculated following the external standard technique using
50 lg mL1 of OLZ and 200 lg mL1 of FLX as the external
standards) versus concentrations and linear correlation was
obtained.trodensitometric and HPLC methods.
HPLC Reference values [18,19]
OLZ FLX
2.74 9.77
12.88 Rs> 2
0.9 1.1 T= 1 for a typical symmetric peak
2.053 8.743 1 < K’ < 10
4.259 a> 1
2774.01 2334.89 N> 2000
0.090 0.107
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Simultaneous determination of olanzapine and ﬂuoxetine hydrochloride in capsules 179The regression equations were computed for OLZ and
FLX and found to be:
A ¼ 0:018Cþ 0:086 ðfor OLZÞ
A ¼ 0:005C 0:004 ðfor FLXÞ
where A is the peak area ratio and C is the corresponding
concentration in lg mL1.
Validation of the proposed methods was done according
to the ICH guidelines. For all the proposed methods, the
intermediate precision and repeatability, the assay parameters
of the regression equations and the concentration ranges are
shown in Table 1.
The proposed methods were successfully applied to the
analysis of OLZ and FLX in their laboratory prepared mix-
tures, Tables 2 and 3 and in capsule dosage form, Table 4.
The validity of the proposed methods was assessed by apply-
ing the standard addition technique, Table 4.
After the proposed TLC-spectrodensitometric and HPLC
methods have been validated, an overall system suitability test-
ingwas done to determine if the operating system is performing
properly. All peak parameters of resolution efﬁciency were cal-
culated and satisfactory results were obtained, Table 5.
Statistical comparison between the results obtained by the
proposed methods and those obtained by the reported HPLC
method was done [14]. The calculated t- and F-values [17]
were found to be less than the corresponding theoretical
ones, conﬁrming good accuracy and excellent precision,
Table 6.
Conclusion
The proposed methods are simple, sensitive, and precise and
could be easily applied in quality control laboratories for the
simultaneous determination of OLZ and FLX.
The advantages of the proposed HPLC method over the
reported ones [13–15] are better resolution (12.88), wider
range (we can determine up to 100 lg mL1 olanzapine and
600 lg mL1 ﬂuoxetine HCl) and less tailed (more symmet-
ric) peaks. The proposed TLC-spectrodensitometric method
has also the advantages of better resolution and wider range
(we can determine up to 8 lg band1 olanzapine and 60 lg
band1 ﬂuoxetine HCl) over the reported ones [14,15].
The proposed methods could be successfully applied for
the routine analysis of the studied drugs either in their pure
bulk powders or in their dosage forms without any prelimin-
ary separation step.
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